Pharmaceutical sciences

Qilu Pharmaceutical and Peptron Sign License Agreement for anti-MUC1 ADC

Friday, April 16, 2021 - 1:00pm

"Qilu is one of the leading pharmaceutical companies with global expertise and capacity in innovative R&D, manufacturing and marketing in China.

Key Points: 
  • "Qilu is one of the leading pharmaceutical companies with global expertise and capacity in innovative R&D, manufacturing and marketing in China.
  • "\nQilu Pharmaceutical is a leading vertically integrated pharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative medicines.
  • To date, Qilu has launched 200+ products with 30+ products "First to launch" in China and 3 products "D181 launch" in US with approximately US$4.2 billion sales revenue in 2020.
  • Peptron is running a GMP manufacturing facility for sustained-release peptide injectables.

Global Pharma, Biotech & Diagnostics Co-promotion and Co-marketing Partnering Terms and Agreements Directory 2014-2021 - ResearchAndMarkets.com

Friday, April 9, 2021 - 12:49pm

The "Global Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech & Diagnostics 2014-2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech & Diagnostics 2014-2021" report has been added to ResearchAndMarkets.com's offering.
  • The Global Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014-2021 report provides comprehensive access to records for over 350 co-promotion and co-marketing deals.
  • This report provides details of the latest co-promotion and co-marketing agreements announced in the pharmaceutical, biotechnology and diagnostic sectors.
  • Global Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014-2021 includes:
    Available contracts are listed by:
    Analyzing actual contract agreements allows assessment of the following:
    What are the precise co-promotion and co-marketing rights granted or optioned?

ZA Group Inc. Reports Increased Demand and Rapid Expansion with their Canadian Cannabis Grow Subsidiary

Thursday, April 8, 2021 - 3:30pm

An explosion in pre-orders have required us to carefully ramp up operations to meet distribution needs throughout the entire community's dispensaries.

Key Points: 
  • An explosion in pre-orders have required us to carefully ramp up operations to meet distribution needs throughout the entire community's dispensaries.
  • Additionally, correspondence is pouring in requesting that the company launch and manage several new dispensaries throughout the province.
  • Projected revenues for each pod per grow cycle is nearly $100,000, with the ability of up to four grow cycles per year.
  • What sets our company apart is our ability to transport, and this unprecedented strategy will change the face of Cannabis Worldwide."

The First Round of Easyriders Products Hit Shops this Month

Thursday, April 8, 2021 - 2:00pm

The collaboration officially hits the road this month with premium pre-roll packs in silver or black collectible tins featuring the iconic Easyriders logo.

Key Points: 
  • The collaboration officially hits the road this month with premium pre-roll packs in silver or black collectible tins featuring the iconic Easyriders logo.
  • Both are terpene-rich, indica-dominant hybrids that may promote stress release, physical relaxation and uplifting moods.
  • These initial products in the Easyriders line will be available at dispensaries throughout California.
  • Hollister Biosciences Inc. is a multi-state cannabis company with a vision to be the sought-after premium brand portfolio of innovative, high-quality cannabis & hemp products.

Green Thumb Industries to Hold First Quarter 2021 Earnings Conference Call on May 12, 2021

Thursday, April 8, 2021 - 12:00pm

The earnings conference call may be accessed by dialing 833-502-0470 (Toll-Free) or 236-714-2182 (International) with conference ID: 6438759.

Key Points: 
  • The earnings conference call may be accessed by dialing 833-502-0470 (Toll-Free) or 236-714-2182 (International) with conference ID: 6438759.
  • Green Thumb Industries Inc. (Green Thumb), a national cannabis consumer packaged goods company and retailer, promotes well-being through the power of cannabis while giving back to the communities in which it serves.
  • Green Thumb manufactures and distributes a portfolio of branded cannabis products including Beboe, Dogwalkers, Dr. Solomons, incredibles, Rythm and The Feel Collection.
  • Headquartered in Chicago, Illinois, Green Thumb has 13 manufacturing facilities, licenses for 97 retail locations and operations across 12 U.S. markets.

Burger's Medicinal Chemistry, Drug Discovery and Development, 8 Volume Set, Volumes 1-8 - ResearchAndMarkets.com

Wednesday, April 7, 2021 - 3:10pm

The "Burger's Medicinal Chemistry, Drug Discovery and Development, 8 Volume Set.

Key Points: 
  • The "Burger's Medicinal Chemistry, Drug Discovery and Development, 8 Volume Set.
  • Volumes 1 - 8" book from John Wiley and Sons Ltd has been added to ResearchAndMarkets.com's offering.
  • This flagship reference for medicinal chemists and pharmaceutical professionals has been thoroughly updated and expanded to incorporate the concepts of drug hunting along with its existing coverage of the entire process of drug discovery and development.
  • Features thematic volumes or sections on drug discovery, drug development, cardiovascular diseases, metabolic diseases, immunology, cancer, antiinfectives, and CNS disorders.

Prime Therapeutics studies: Integrated pharmacy, medical data inform effective drug therapy management for high-cost conditions

Wednesday, April 7, 2021 - 1:00pm

Recently, Prime analyzed integrated pharmacy and medical claims data for specialty drug use in autoimmune conditions the top cost drivers among all drug health care expenses.

Key Points: 
  • Recently, Prime analyzed integrated pharmacy and medical claims data for specialty drug use in autoimmune conditions the top cost drivers among all drug health care expenses.
  • With the drug therapies to treat autoimmune conditions being billed on both the medical and pharmacy benefits, a complete picture can be seen with integrated medical and pharmacy analytics.
  • In addition, these findings are essential to comprehensive medical and pharmacy drug benefit management that health plans are charged with providing for their members.
  • Though less than 1% of Prime's commercially insured members suffer from these conditions, the related drug treatments were approaching 20% of all drug spend through the medical and pharmacy benefit.

Trulieve Brings Medical Cannabis to Dunedin

Tuesday, April 6, 2021 - 9:05pm

The location marks the first dispensary in Dunedin, broadening access to the state's largest inventory of medical cannabis

Key Points: 
  • The location marks the first dispensary in Dunedin, broadening access to the state's largest inventory of medical cannabis
    TALLAHASSEE, Fla., April 6, 2021 /PRNewswire/ - Trulieve Cannabis Corp. (CSE: TRUL) (OTC: TCNNF) ("Trulieve" or "the Company"), a leading and top-performing cannabis company based in the United States, announced today the opening of a brand-new Florida dispensary, the Company's 84th nationwide.
  • The dispensary furthers Trulieve's goal of ensuring direct, reliable access to medical cannabis across its home state of Florida.
  • The company's 79th Florida dispensary joins nearby locations in Tampa, St. Petersburg, and Tarpon Springs and brings direct, in-store access to registered patients in Dunedin for the first time.
  • Trulieve is primarily a vertically integrated "seed-to-sale" company in the U.S. and is the first and largest fully licensed medical cannabis company in the State of Florida.

Regeneron to Report First Quarter 2021 Financial and Operating Results and Host Conference Call and Webcast on May 6, 2021

Tuesday, April 6, 2021 - 9:05pm

TARRYTOWN, N.Y., April 6, 2021 /PRNewswire/ --Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)today announced that it will report its first quarter 2021 financial and operating results on Thursday, May 6, 2021, before the U.S. financial markets open.

Key Points: 
  • TARRYTOWN, N.Y., April 6, 2021 /PRNewswire/ --Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)today announced that it will report its first quarter 2021 financial and operating results on Thursday, May 6, 2021, before the U.S. financial markets open.
  • The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day.
  • A replay of the conference call and webcast will be archived on the Company's website for at least 30 days.
  • Regeneron(NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases.

Innovative Industrial Properties Announces Year-to-Date 2021 Operating, Investment and Capital Markets Activity

Tuesday, April 6, 2021 - 9:30pm

IIP did not conduct any capital raising activities during the year-to-date through April 5, 2021.

Key Points: 
  • IIP did not conduct any capital raising activities during the year-to-date through April 5, 2021.
  • Innovative Industrial Properties, Inc. is a self-advised Maryland corporation focused on the acquisition, ownership and management of specialized industrial properties leased to experienced, state-licensed operators for their regulated medical-use cannabis facilities.
  • Innovative Industrial Properties, Inc. has elected to be taxed as a real estate investment trust, commencing with the year ended December 31, 2017.
  • IIP disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.